Abstract Objective To study the significance of E-cadherin and the association between E-cadherin methylation status and prognosis in children with acute lymphoblastic leukemia (ALL) by examining the mRNA and protein expression of E-cadherin and its gene methylation status in bone marrow mononuclear cells of children with ALL. Methods The samples of 5 mL bone marrow blood were collected from 42 children with ALL who were diagnosed for the first time at diagnosis (pre-treatment group) and on day 33 of induction chemotherapy (post-treatment group). RT-qPCR, Western blot, and methylation-specific PCR were used to measure the mRNA and protein expression of E-cadherin and the methylation level of the E-cadherin gene. The changes in each index after induction chemotherapy were compared. Results The mRNA and protein expression levels of E-cadherin in the post-treatment group were significantly higher than those in the pre-treatment group (P<0.05), while the positive rate of E-cadherin gene methylation in the post-treatment group was significantly lower than that in the pre-treatment group (P<0.05). At the end of the test, the children with negative methylation had significantly higher overall survival rate and event-free survival rate than those with positive methylation (P<0.05). Conclusions E-cadherin expression is associated with the development of ALL in children, and its decreased expression and increased methylation level may indicate a poor prognosis.
QI Feng-Qi,HAN Wei,YAN Jing et al. Influence of E-cadherin methylation on prognosis in children with acute lymphoblastic leukemia[J]. CJCP, 2023, 25(1): 46-50.
QI Feng-Qi,HAN Wei,YAN Jing et al. Influence of E-cadherin methylation on prognosis in children with acute lymphoblastic leukemia[J]. CJCP, 2023, 25(1): 46-50.
Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review[J]. Anticancer Res, 2020, 40(11): 6009-6015. PMID: 33109539. DOI: 10.21873/anticanres.14622.
Loh CY, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges[J]. Cells, 2019, 8(10): 1118. PMID: 31547193. PMCID: PMC6830116. DOI: 10.3390/cells8101118.
Zhou C, Yang C, Chong D. E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer: a PRISMA-compliant meta-analysis[J]. Medicine (Baltimore), 2019, 98(30): e16187. PMID: 31348230. PMCID: PMC6709073. DOI: 10.1097/MD.0000000000016187.
Ye CC, Wang J. E-cadherin (CDH1) gene -160C/A polymorphism and the risk of colorectal cancer: a meta-analysis involving 17,291 subjects[J]. J Gene Med, 2021, 23(10): e3370. PMID: 34097324. DOI: 10.1002/jgm.3370.
Abdullah M, Choo CW, Alias H, et al. ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia[J]. Hematology, 2017, 22(7): 386-391. PMID: 28292214. DOI: 10.1080/10245332.2017.1299417.
Bure IV, Nemtsova MV, Zaletaev DV. Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer[J]. Int J Mol Sci, 2019, 20(12): 2870. PMID: 31212809. PMCID: PMC6627057. DOI: 10.3390/ijms20122870.
Katoh M. Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β?catenin signaling activation (review)[J]. Int J Mol Med, 2018, 42(2): 713-725. PMID: 29786110. PMCID: PMC6034925. DOI: 10.3892/ijmm.2018.3689.
Wong KK. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications[J]. Cell Oncol (Dordr), 2020, 43(5): 779-792. PMID: 32504382. DOI: 10.1007/s13402-020-00526-4.
McCormick TM, Canedo NH, Furtado YL, et al. Association between human papillomavirus and Epstein-Barr virus DNA and gene promoter methylation of RB1 and CDH1 in the cervical lesions: a transversal study[J]. Diagn Pathol, 2015, 10: 59. PMID: 26032781. PMCID: PMC4450846. DOI: 10.1186/s13000-015-0283-3.
